

- Chen KC, Chow WH, Ji BT, Chan JK, Chu M, Li YJ, Yokota J, Li J, Chen H, Xiang YB, Yu CJ, Kunitoh H, Wu G, Jin L, Lo YL, Shiraishi K, Chen YH, Lin HC, Wu T, Wu YL, Yang PC, Zhou B, Shin MH, Fraumeni JF. Jr, Lin D, Chanock SJ, Rothman N. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nat Genet* 2012;44:1330-1335.
- 13) Yoshida A, Kohno T, Tsuta K, Wakai S, Shimada Y, Arai Y, Asamura H, Furuta K, Shibata T, Tsuda H. ROS1-Rearranged Lung Cancer: Clinicopathologic and Molecular Study of 15 Surgical Cases. *Am J Surg Pathol* 2013;37:554-562.
  - 14) Kohno T, Shiraishi K. Genetic polymorphisms underlying lung cancer susceptibility and therapeutic Response. *Genes and Environment* 2012;34:94-100.
  - 15) Shiba-Ishii A, Noguchi M. Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma. *Am J Pathol* 2012;180:1653-1662.
  - 16) Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, Goya T, Noguchi M. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. *Lang Cancer* 2012;75:181-188.
  - 17) Nakazato Y, Maeshima MA, Ishikawa Y, Yatabe Y, Fukuoka J, Yokose T, Tomita Y, Minami Y, Asamura Y, Tachibana K, Goya T, Noguchi M. Inter observer agreement in the nuclear grading of primary pulmonary adenocarcinoma. *J Thorac Oncol*, in press.
  - 18) Yamagishi M, Nakano K, Miyake A, Yamochi T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S, Utsunomiya A, Yamaguchi K, Uchimaru K, Ogawa S, Watanabe T. Polycomb-mediated loss of miR-31 activates NIK-dependent NF- $\kappa$ B pathway in adult T-cell leukemia and other cancers. *Cancer Cell* 2012;21:121-135.
  - 19) Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K, Niwa A, Nishikomori R, Kambe N, Hara H, Mitsuyama M, Morone N, Heuser JE, Yamamoto T, Watanabe A, Sato-Otsubo A, Ogawa S, Asaka I, Heike T, Yamanaka S, Nakahata T, Saito MK. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. *Blood* 2012;120:1299-1308.
  - 20) Takita J, Yoshida K, Sanada M, Nishimura R, Okubo J, Motomura A, Hiwatari M, Oki K, Igarashi T, Hayashi Y, Ogawa S. Novel splicing-factor mutations in juvenile myelomonocytic leukemia. *Leukemia* 2012;26:1879-1881.
  - 21) Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K. Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. *Cancer Sci* 2012;103:782-790.
  - 22) Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K. The Increased Expression of Integrin  $\alpha$ 6 (ITGA6) Enhances Drug Resistance in EVI1 Leukemia. *PLoS One* 2012;7:e30706.
  - 23) Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. *Leukemia* 2012;26:1238-1246.
  - 24) Nakahata S, Morishita K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. *J Clin Exp Hematop* 2012;52:17-22.
  - 25) Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56, *Leukemia*, in press.
  - 26) Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T. Mouse model fro ROS1-rearranged lung cancer. *PLoS One*, in press.
  - 27) Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T, Tototki Y, Kosuge T, Miyagawa S, Shibata T. Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. *Cancer Sci*, in press.
  - 28) Yoshida A, Shibata T, Wakai S, Ushiku T, Tsuta K, Fukayama M, Makimoto A, Furuta K, Tsuda H. Anaplastic lymphoma kinase (ALK) status in rhabdomyosarcoma. *Modern Pathology*, in press.
  - 29) Nakagawa H, Shibata T. Comprehensive genome sequencing of liver cancer (Review). *Cancer Letters*, in press.
  - 30) Shibata T. Cancer genomics and pathology: All Together Now (Review). *Patho Int* 2012;62:647-659.
  - 31) Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. *Cancer Cell* 2012;22:66-79.
  - 32) Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hoshono N, Kubo M, Miya F,

- Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakao K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamae H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole Genome Sequencing of Liver Cancers Identifies Etiological Influences on Mutation Patterns and Recurrent Mutations in Chromatin Regulators. *Nature Genet* 2012;44:760-764.
- 33) Arima Y, Hayashi H, Sasaki M, Hosonaga M, Goto TM, Chiyoda T, Kuninaka S, Shibata T, Ohata H, Nakagama H, Taya Y, Sata H. Induction of ZEB by inactivation of RB is a key determinant of the mesenchymal phenotype of breast cancer. *J Biol Chem* 2012;287:7896-7906.
  - 34) Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, Shibata T. MDM2 and CDK4 Immunohistochemical Coexpression in High-Grade Osteosarcoma: Correlation with a Dedifferentiated Subtype. *Am J Surg Pathol* 2012;36:423-431.
  - 35) Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Hirono S, Yamae H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Hiroki U, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. *Genome Res* 2012;22:208-219.
  - 36) Harazono Y, Kozaki K, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J. miR-655 is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. *PLOS ONE*, in press.
  - 37) Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, Niida A, Miyano S, Inazawa J. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. *PLOS ONE*, in press.
  - 38) Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, Inazawa J, Kozaki K. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. *Carcinogenesis* 2013;34:560-569.
  - 39) Miyawaki Y, Imoto I, Tokairin Y, Kawada K, Nakajima Y, Nishikage T, Nagai K, Kajiwara M, Inazawa J, Kawano T. Esophageal Squamous Cell Carcinoma Developed 11 Years After Allogeneic Bone Marrow Transplantation for Acute Lymphatic Leukemia. *Jpn J Clin Oncol* 2013;43:69-73.
  - 40) Gaffney CJ, Oka T, Mazack V, Hilman D, Gat U, Muramatsu T, Inazawa J, Golden A, Carey DJ, Farooq A, Tromp G, Sudol M. Identification, basic characterization and evolutionary analysis of differentially spliced mRNA isoforms of human YAP1 gene. *Gene* 2012;509:215-222.
  - 41) Dobashi Y, Kimura M, Matsubara H, Endo S, Inazawa J, Ooi A. Molecular alterations in AKT and its protein activation in human lung carcinomas. *Hum Pathol* 2012;43:2229-2240.
  - 42) Miyawaki Y, Kawachi H, Ooi A, Eishi Y, Kawano T, Inazawa J, Imoto I. Genomic copy-number alterations of MYC and FHIT genes are associated with survival in esophageal squamous-cell carcinoma. *Cancer Sci* 2012;103:1558-1566.
  - 43) Matsumura S, Imoto I, Kozaki K, Matsui T, Muramatsu T, Furuta M, Tanaka S, Sakamoto M, Arii S, Inazawa J. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor-suppressor in hepatocellular carcinoma. *Clin Cancer Res* 2012;18:3541-3551.
  - 44) Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, Kubo M, Furihata M, Kamatani N, Inazawa J, Chen GK, Le Marchand L, Kolonel LN, Katoh T, Yamano Y, Yamakado M, Takahashi H, Yamada H, Egawa S, Fujioka T, Henderson BE, Habuchi T, Ogawa O, Nakamura Y, Nakagawa H. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. *Nat Genet* 2012;44:426-429.
  - 45) Yamamoto S, Tsuda H, Honda K, Takano M, Tamai S, Imoto I, Inazawa J, Yamada T, Matsubara O. ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. *Histopathology* 2012;60:1073-1083.
  - 46) Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, Muramatsu T, Sugihara K, Inazawa J. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. *Oncogene* 2012;31:4923-4934.
  - 47) Bai H, Inoue J, Kawano T, Inazawa J. A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers. *Oncogene* 2012;31:4397-4408.
  - 48) Ooi A, Inokuchi M, Harada S, Inazawa J, Tajiri R, Sawada-Kitamura S, Ikeda H, Kawashima H, Dobashi Y. Gene amplification of ESR1 in breast cancers - Fact or fiction? A fluorescence in situ hybridization and multiplex ligation-dependent probe amplification study. *J Pathol* 2012;227:8-16.
  - 49) Kurasawa Y, Kozaki K, Pimkhaokham A, Muramatsu T, Ono H, Ishihara T, Uzawa N, Imoto I, Amagasa T, Inazawa

J. Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells. *Oncogene* 2012;31:1963-1974.

